Pediatric Nephrology

, Volume 20, Issue 11, pp 1515–1522 | Cite as

Glycation free adduct accumulation in renal disease: the new AGE

Editorial Commentary

Abstract

Glycation adducts formed in the later stages of protein glycation reactions, advanced glycation endproducts (AGEs), are a class of uraemic toxin. Protein glycation was viewed originally as a post-translational modification that accumulated mostly on extracellular proteins. We now know that AGE residues are also formed on short-lived cellular and extracellular proteins. Cellular proteolysis forms AGE free adducts from these proteins, which are released into plasma for urinary excretion. AGE free adducts are also absorbed from food. AGE free adducts are the major molecular form by which AGEs are excreted in urine. They normally have high renal clearance, but this declines markedly in chronic renal failure patients, leading to profound increases in plasma AGE free adducts. Accumulation of plasma AGE free adducts is increased further in end stage renal disease patients on peritoneal dialysis and haemodialysis by increased AGE formation. The impact of AGEs absorbed from food is probably most marked for undialysed patients with mild uraemia. The toxicity of AGEs has been associated with resistance of the extracellular matrix to proteolysis and AGE receptor-mediated responses. AGE free adducts may also contribute to vascular disease in uraemia. They represent an important new age for glycation research in nephrology.

Keywords

Glycation Chronic renal failure Haemodialysis Peritoneal dialysis Uraemia 

Notes

Acknowledgements

I thank the Wellcome Trusts and Baxter Healthcare Inc. (Illinois, USA) for support for my uraemia research.

References

  1. 1.
    Thornalley PJ (1999) Clinical significance of glycation. Clin Lab 45:263–273Google Scholar
  2. 2.
    Thornalley PJ, Battah S, Ahmed N, Karachalias N, Agalou S, Babaei-Jadidi R, Dawnay A (2003) Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 375:581–592CrossRefPubMedGoogle Scholar
  3. 3.
    Hammes H-P, Brownlee M, Liu J, Schleicher E, Bretzel RG (1999) Diabetic retinopathy risk correlates with intracellular concentrations of the glycoxidation product Nε-(carboxymethyl)lysine independently of glycohaemoglobin concentrations. Diabetologia 42:603–607CrossRefPubMedGoogle Scholar
  4. 4.
    Sebekova K, Podracka L, Blazicek P, Syrova D, Heidland A, Schinzel R (2001) Plasma levels of advanced glycation end products in children with renal disease. Pediatr Nephrol 16:1105–1112CrossRefPubMedGoogle Scholar
  5. 5.
    Fukunaga Y, Katsuragi Y, Izumi T, Sakiyama F (1982) Fluorescence characteristics of kynurenine and N′-formylkynurenine. Their use as reporters of the environment of tryptophan 62 in hen egg-white lysozyme. J Biochem 92:129–141PubMedGoogle Scholar
  6. 6.
    Odetti P, Fogarty J, Sell DR, Monnier VM (1992) Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects. Diabetes 41:153–159PubMedGoogle Scholar
  7. 7.
    Wilker SC, Chellan P, Arnold BM, Nagaraj RH (2001) Chromatographic quantification of argpyrimidine, a methylglyoxal-derived product in tissue proteins. Anal Biochem 290:353–358CrossRefPubMedGoogle Scholar
  8. 8.
    Verzijl N, DeGroot J, Thorpe SR, Bank RA, Shaw JN, Lyons TJ, Bijlsma JWJ, Lafeberi FPJG, Baynes JW, TeKoppele JM (2000) Effect of collagen turnover on the accumulation of advanced glycation endproducts. J Biol Chem 275:39027–39031CrossRefPubMedGoogle Scholar
  9. 9.
    Goldberg AL (2003) Protein degradation and protection against misfolded or damaged proteins. Nature 426:895–899CrossRefPubMedGoogle Scholar
  10. 10.
    Gerner C, Vejda S, Gelbmann D, Bayer E, Gotzmann J, Schulte-Hermann R, Mikulitis W (2002) Concomitant determination of absolute values of cellular protein amounts, synthesis rates, and turnover rates by quantitative proteome profiling. Mol Cell Proteomics 1:528–537CrossRefPubMedGoogle Scholar
  11. 11.
    Agalou S, Ahmed N, Babaei-Jadidi R, Dawnay A, Thornalley PJ (2005) Profound mishandling of protein glycation degradation products in uremia and dialysis. J Am Soc Nephrol 16:1471–1485CrossRefPubMedGoogle Scholar
  12. 12.
    Suzuki D, Miyata T, Saotome N, Horie K, Inagi R, Yasuda Y, Uchida K, Izuhara Y, Yagame M, Sakai H, Kurokawa K (1999) Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol 10:822–832PubMedGoogle Scholar
  13. 13.
    Delpierre G, Vertommen D, Communi D, Rider MH, Van Schaftingen E (2004) Identification of fructosamine residues deglycated by fructosamine-3-kinase in human hemoglobin. J Biol Chem 279:27613–27620CrossRefPubMedGoogle Scholar
  14. 14.
    Szwergold BS, Howell S, Beisswenger PJ (2001) Human fructosamine-3-kinase. Purification, sequencing, substrate specificity, and evidence of activity in vivo. Diabetes 50:2139–2147PubMedGoogle Scholar
  15. 15.
    Delpierre G, Collard F, Fortpied J, Van Schaftingen E (2002) Fructosamine 3-kinase is involved in an intracellular deglycation pathway in human erythrocytes. Biochem J 365:801–808PubMedGoogle Scholar
  16. 16.
    Layton GJ, Allen TJ, Jerums G (1990) Longitudinal evaluation of the renal clearance of glycated albumin in the diabetic rat. Diabetes Res Clin Pract 8:221–226CrossRefPubMedGoogle Scholar
  17. 17.
    Takahashi M, Fujii J, Teshima T, Suzuki K, Shiba T, Taniguchi N (1993) Identity of a major 3-deoxyglucosone-reducing enzyme with aldehyde reductase in rat liver established by amino acid sequencing and cDNA expression. Gene 127:249–253CrossRefPubMedGoogle Scholar
  18. 18.
    Ahmed N, Dobler D, Dean M, Thornalley PJ (2005) Peptide mapping identifies hotspot site of modification in human serum albumin by methylglyoxal involved in ligand binding and esterase activity. J Biol Chem 280:5724–5732CrossRefPubMedGoogle Scholar
  19. 19.
    Thornalley PJ (2003) Glyoxalase I—structure, function and a critical role in the enzymatic defence against glycation. Biochem Soc Trans 31:1343–1348PubMedGoogle Scholar
  20. 20.
    Ahmed N, Argirov OK, Minhas HS, Cordeiro CA, Thornalley PJ (2002) Assay of advanced glycation endproducts (AGEs): surveying AGEs by chromatographic assay with derivatisation by aminoquinolyl-N-hydroxysuccimidyl-carbamate and application to Nε-carboxymethyl-lysine- and Nε-(1-carboxyethyl)lysine-modified albumin. Biochem J 364:1-14PubMedGoogle Scholar
  21. 21.
    Gallet X, Charloteaux B, Thomas A, Braseur R (2000) A fast method to predict protein interaction sites from sequences. J Mol Biol 302:917–926CrossRefPubMedGoogle Scholar
  22. 22.
    Ahmed N, Thornalley PJ, Dawczynski J, Franke S, Strobel J, Stein G, Haik JR GM (2003) Methylglyoxal-derived hydroimidazolone advanced glycation endproducts of human lens proteins. Invest Ophthalmol Vis Sci 44:5287–5292CrossRefPubMedGoogle Scholar
  23. 23.
    Thornalley PJ (2005) Dicarbonyl intermediates in the Maillard reaction. Ann N Y Acad Sci 1043:118Google Scholar
  24. 24.
    Thornalley PJ, Argirova M, Ahmed N, Mann VM, Argirov OK, Dawnay A (2000) Mass spectrometric monitoring of albumin in uraemia. Kidney Int 58:2228–2234CrossRefPubMedGoogle Scholar
  25. 25.
    Ahmed N, Thornalley PJ (2002) Chromatographic assay of glycation adducts in human serum albumin glycated in vitro by derivatisation with aminoquinolyl-N-hydroxysuccimidyl-carbamate and intrinsic fluorescence. Biochem J 364:15–24PubMedGoogle Scholar
  26. 26.
    Henle T (2003) AGEs in foods: do they play a role in uremia? Kidney Int 63:S145–S147CrossRefGoogle Scholar
  27. 27.
    Johnson RN, Easdale RW, Tatnell M, Baker JR (1991) Significance of variation in turnover of glycated albumin on indexes of diabetic control. Clin Chim Acta 198:229–238CrossRefPubMedGoogle Scholar
  28. 28.
    Ahmed N, Thornalley PJ, Luthen R, Haussinger D, Sebekova K, Schinzel R, Voelker W, Heidland A (2004) Processing of protein glycation, oxidation and nitrosation adducts in the liver and the effect of cirrhosis. J Hepatol 41:913–919CrossRefPubMedGoogle Scholar
  29. 29.
    Russo LM, Bakris GL, Comper WD (2002) Renal handling of albumin: a critical review of basic concepts and perspective. Am J Kidney Dis 39:899–919CrossRefPubMedGoogle Scholar
  30. 30.
    Cha T, Tahara Y, Yamoto E, Yoneda H, Ikegami H, Noma Y, Shima K, Ogihara T (1991) Renal handling of glycated albumin in non-insulin-dependent diabetes mellitus with nephropathy. Diabetes Res Clin Pract 12:149–156CrossRefPubMedGoogle Scholar
  31. 31.
    Bendayan M, Londono I (1996) Reabsorption of native and glycated albumin by renal proximal tubular epithelial cells. Am J Physiol 40:F261–F268Google Scholar
  32. 32.
    Greive KA, Balazs NDH, Comper WD (2001) Protein fragments in urine have been considerably underestimated by various protein assays. Clin Chem 47:1717–1719PubMedGoogle Scholar
  33. 33.
    Ahmed N, Babaei-Jadidi R, Howell SK, Beisswenger PJ, Thornalley PJ (2005) Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes. Diabetologia (in press)Google Scholar
  34. 34.
    Koschinsky T, He C-J, Mitsuhashi T, Bucala R, Liu C, Buenting C, Heitman K, Vlassara H (1997) Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A 94:6474–6479Google Scholar
  35. 35.
    Cai WJ, Gao QD, Zhu L, Peppa M, He CJ, Vlassara H (2002) Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction. Mol Med 8:337–346PubMedGoogle Scholar
  36. 36.
    Vlassara H, Cai WJ, Crandall J, Goldberg T, Oberstein R, Dardaine V, Peppa M, Rayfield EJ (2002) Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A 99:15596–15601Google Scholar
  37. 37.
    Uribarri J, Peppa M, Cai WJ, Goldberg T, Lu M, Baliga S, Vassalotti JA, Vlassara H (2003) Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients. Am J Kidney Dis 42:532–538CrossRefPubMedGoogle Scholar
  38. 38.
    Ahmed N, Mirshekar-Syahkal B, Kennish L, Karachalias N, Babaei-Jadidi R, Thornalley PJ (2005) Assay of advanced glycation endproducts in selected beverages and food by liquid chromatography with tandem mass spectrometric detection. Mol Nutr Food Res 49:691–699CrossRefPubMedGoogle Scholar
  39. 39.
    He C, Sabol J, Mitsuhashi T, Vlassara H (1999) Dietary glycotoxins. Inhibition of reactive products by aminoguanidine facilitates renal clearance and reduced tissue sequestration. Diabetes 48:1308–1315PubMedGoogle Scholar
  40. 40.
    Thornalley PJ, Langborg A, Minhas HS (1999) Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 344:109–116CrossRefPubMedGoogle Scholar
  41. 41.
    Thornalley PJ (2003) Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 419:31–40CrossRefPubMedGoogle Scholar
  42. 42.
    Thornalley PJ (1988) Modification of the glyoxalase system in human red blood cells by glucose in vitro. Biochem J 254:751–755PubMedGoogle Scholar
  43. 43.
    Nagao M, Fujita Y, Sugimura T, Kosuge T (1986) Methylglyoxal in beverages and foods its mutagenicity and carcinogenicity. IARC Sci Publ 70:283–291PubMedGoogle Scholar
  44. 44.
    Hayashi T, Shibamoto T (1985) Analysis of methylglyoxal in foods and beverages. J Agric Food Chem 33:1090–1093CrossRefGoogle Scholar
  45. 45.
    Mortier S, Faict D, Schalkwijk CG, Lameire NH, De Vriese AS (2004) Long-term exposure to new peritoneal dialysis solutions: effects on the peritoneal membrane. Kidney Int 66:1257–1265CrossRefPubMedGoogle Scholar
  46. 46.
    Oste RE, Miller R, Sjostrom H, Noren O (1987) Effect of Maillard reaction products on protein digestion—studies on pure compounds. J Agric Food Chem 35:938–942CrossRefGoogle Scholar
  47. 47.
    Sinha R, Fisch G, Teague B, Tamborlane WV, Banyas B, Allen K, Savoye M, Rieger V, Taksali S, Barbetta G, Sherwin RS, Caprio S (2002) Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 346:802–810CrossRefPubMedGoogle Scholar
  48. 48.
    Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, UK Prospective Diabetes Study Group (2003) Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63:225–252CrossRefPubMedGoogle Scholar
  49. 49.
    Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ (2003) Prevention of incipient diabetic nephropathy by high dose thiamine and Benfotiamine. Diabetes 52:2110–2120PubMedGoogle Scholar
  50. 50.
    Litwin M, Wuhl E, Jourdan C, Trelewicz J, Niemirska A, Fahr K, Jobs K, Grenda R, Wawer ZT, Rajszys P, Troger J, Mehls O, Schaefer F (2005) Altered morphologic properties of large arteries in children with chronic renal failure and after renal transplantation. J Am Soc Nephrol 16:1494–1500CrossRefPubMedGoogle Scholar
  51. 51.
    Chavers BM, Li S, Collins AJ, Herzog CA (2002) Cardiovascular disease in pediatric chronic dialysis patients. Kidney Int 62:648–653CrossRefPubMedGoogle Scholar
  52. 52.
    Misselwitz J, Franke S, Kauf E, John U, Stein G (2002) Advanced glycation end products in children with chronic renal failure and type 1 diabetes. Pediatr Nephrol 17:316–321CrossRefPubMedGoogle Scholar
  53. 53.
    Bayazit AK, Vogt BA, Dell KM, Davis ID, Noyan A, Anarat A, Avner ED, Erhard P, Weiss MF (2003) Effect of the peritoneal dialysis prescription on pentosidine in children. Pediatr Nephrol 18:1049–1054CrossRefPubMedGoogle Scholar
  54. 54.
    Sebekova K, Podracka L, Heidland A, Schinzel R (2001) Enhanced plasma levels of advanced glycation end products (AGE) and pro-inflammatory cytokines in children/adolescents with chronic renal insufficiency and after renal replacement therapy by dialysis and transplantation—are they inter-related? Clin Nephrol 56:S21–S26PubMedGoogle Scholar
  55. 55.
    Flynn JT (2002) Choice of dialysis modality for management of pediatric acute renal failure. Pediatr Nephrol 17:61–69CrossRefPubMedGoogle Scholar
  56. 56.
    Leonard MB, Donaldson LA, Ho M, Geary DF (2003) A prospective cohort study of incident maintenance dialysis in children: an NAPRTC study. Kidney Int 63:744–755CrossRefPubMedGoogle Scholar
  57. 57.
    Schroder CH (2001) The choice of dialysis solutions in pediatric chronic peritoneal dialysis: guidelines by an ad hoc European committee. Perit Dial Int 21:568–574PubMedGoogle Scholar
  58. 58.
    Deguchi T, Kusuhara H, Takadate A, Endou H, Otagiri M, Sugiyama Y (2004) Characterization of uremic toxin transport by organic anion transporters in the kidney. Kidney Int 65:162–174CrossRefPubMedGoogle Scholar
  59. 59.
    Mann GE, Yudilevich DL, Sobrevia L (2003) Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. Physiol Rev 83:183–252PubMedGoogle Scholar
  60. 60.
    Deuther-Conrad W, Franke S, Sommer M, Henle T, Stein G (2001) Differences in the modulating potential of advanced glycation (AGE) peptides versus AGE proteins. Kidney Int 59:S63–S66CrossRefGoogle Scholar
  61. 61.
    Yoshihara K, Okumura T, Yoshida T, Beppu M (2001) Inhibitory effect of peptide-free forms of advanced glycation end products on the proliferation and extracellular matrix protein production of cultured cells. J Health Sci 47:296–301CrossRefGoogle Scholar
  62. 62.
    Thornalley PJ (1998) Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol Biol 44:1013–1023PubMedGoogle Scholar
  63. 63.
    Thornalley PJ (2004) Glycation, receptor-mediated cell activation and vascular complications of diabetes. Diabetes Vasc Dis Res 1:21–22Google Scholar
  64. 64.
    Kuzuya M, Asai T, Kanda S, Maeda K, Cheng XW, Iguchi A (2001) Glycation cross-links inhibit matrix metalloproteinase-2 activation in vascular smooth muscle cells cultured on collagen lattice. Diabetologia 44:436CrossRefGoogle Scholar
  65. 65.
    Lindsay RM, Nesrallah G, Suri R, Garg A, Moist L (2004) Is more frequent hemodialysis beneficial and what is the evidence? Curr Opinion Nephrol Hypertens 13:631–635CrossRefGoogle Scholar

Copyright information

© IPNA 2005

Authors and Affiliations

  1. 1.Department of Biological SciencesUniversity of EssexColchesterUK

Personalised recommendations